Jim Simons Xtl Biopharmaceuticals LTD Transaction History
Renaissance Technologies LLC
- $63.6 Billion
- Q1 2024
Shares
6 transactions
Others Institutions Holding XTLB
# of Institutions
6Shares Held
458KCall Options Held
0Put Options Held
0-
Noked Capital LTD Tel Aviv, L3199KShares$483,2970.02% of portfolio
-
Noked Israel LTD Ramat Hasharon, L3199KShares$483,2970.15% of portfolio
-
Morgan Stanley New York, NY39.2KShares$95,1850.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il13.6KShares$33,1230.0% of portfolio
-
Ubs Group Ag6.95KShares$16,8980.0% of portfolio
About XTL BIOPHARMACEUTICALS LTD
- Ticker XTLB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,449,060
- Market Cap $13.2M
- Description
- XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Ye...